Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2010 (2010), Article ID 503593, 8 pages
Review Article

Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials

1EFS-PM, Laboratoire d'Ingénierie Cellulaire, GECSoM, 75 rue de Lisieux, 31300 Toulouse, France
2Service Recherche, EFS-CA, GECSoM, 2 boulevard Tonnellé BP52009, 37020 Tours Cedex 1, France
3UMR 5241 Métabolisme, Plasticité et Mitochondrie, BP84225, 31432 Toulouse Cedex 4, France
4Service de Cardiologie, CHU Rangueil, TSA 50032 1 avenue Jean Poulhes, 31059 Toulouse Cedex 9, France
5Service de Médecine Vasculaire, CHU Rangueil, TSA 50032 1 avenue Jean Poulhes, 31059 Toulouse Cedex 9, France

Received 9 June 2010; Revised 16 August 2010; Accepted 19 September 2010

Academic Editor: J. Gimble

Copyright © 2010 Bourin Philippe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Present in numerous tissues, mesenchymal stem cells/multipotent stromal cells (MSCs) can differentiate into different cell types from a mesoderm origin. Their potential has been extended to pluripotency, by their possibility of differentiating into tissues and cells of nonmesodermic origin. Through the release of cytokines, growth factors and biologically active molecules, MSCs exert important paracrine effects during tissue repair and inflammation. Moreover, MSCs have immunosuppressive properties related to non-HLA restricted immunosuppressive capacities. All these features lead to an increasing range of possible applications of MSCs, from treating immunological diseases to tissue and organ repair, that should be tested in phase I and II clinical trials. The most widely used MSCs are cultured from bone marrow or adipose tissue. For clinical trial implementation, BM MSCs and ADSCs should be produced according to Good Manufacturing Practices. Safety remains the major concern and must be ensured during culture and validated with relevant controls. We describe some applications of MSCs in clinical trials.